Stock DEVA DEVA HOLDING
Add to a list
To use this feature you must be a member
Log inSign up

Financials Deva Holding

Equities

DEVA

TRADEVAW91E2

Pharmaceuticals

Delayed Borsa Istanbul
Other stock markets
 15:36:11 15/05/2024 BST 		5-day change 1st Jan Change
79.4 TRY +1.47% Intraday chart for Deva Holding +3.86% +5.16%
02-12 Tod's rises 17% on L Catterton bids to help owner's delisting plan RE
2023 Deva Holding A.S. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI

Valuation

Fiscal Period: December 2017 2018 2019 2020 2021 2022
Capitalization 1 876.1 658.1 1,798 4,828 5,749 13,841
Enterprise Value (EV) 1 1,287 1,265 2,321 5,313 6,172 15,904
P/E ratio 9.52 x 4.84 x 6.29 x 7.41 x 4.91 x 10.2 x
Yield - - 1.11% 0.41% 0.52% 0.22%
Capitalization / Revenue 1.09 x 0.63 x 1.31 x 2.59 x 2.47 x 3.09 x
EV / Revenue 1.61 x 1.22 x 1.69 x 2.85 x 2.65 x 3.55 x
EV / EBITDA 7.61 x 4.42 x 5.3 x 7.8 x 6.84 x 11.9 x
EV / FCF -7.57 x -4.03 x -54.5 x -17.6 x -10.3 x -7.42 x
FCF Yield -13.2% -24.8% -1.84% -5.67% -9.67% -13.5%
Price to Book 1.45 x 0.88 x 1.74 x 2.95 x 2.11 x 3.52 x
Nbr of stocks (in thousands) 200,019 200,019 200,019 200,019 200,019 200,019
Reference price 2 4.380 3.290 8.990 24.14 28.74 69.20
Announcement Date 10/03/18 08/03/19 06/03/20 05/03/21 04/03/22 10/03/23
1TRY in Million2TRY
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2017 2018 2019 2020 2021 2022
Net sales 1 800.3 1,041 1,374 1,863 2,330 4,478
EBITDA 1 169 285.9 438.1 680.8 901.9 1,340
EBIT 1 138.1 251 399.9 633.3 841.1 1,256
Operating Margin 17.26% 24.12% 29.1% 33.99% 36.09% 28.05%
Earnings before Tax (EBT) 1 94.58 156 280.7 646.5 1,158 1,300
Net income 1 92.54 136.4 286 651.4 1,170 1,360
Net margin 11.56% 13.1% 20.82% 34.96% 50.21% 30.38%
EPS 2 0.4600 0.6800 1.430 3.257 5.850 6.800
Free Cash Flow 1 -169.9 -313.5 -42.59 -301.3 -597.1 -2,142
FCF margin -21.23% -30.12% -3.1% -16.17% -25.62% -47.84%
FCF Conversion (EBITDA) - - - - - -
FCF Conversion (Net income) - - - - - -
Dividend per Share - - 0.1000 0.1000 0.1500 0.1500
Announcement Date 10/03/18 08/03/19 06/03/20 05/03/21 04/03/22 10/03/23
1TRY in Million2TRY
Estimates

Balance Sheet Analysis

Fiscal Period: December 2017 2018 2019 2020 2021 2022
Net Debt 1 410 606 523 484 423 2,063
Net Cash position 1 - - - - - -
Leverage (Debt/EBITDA) 2.428 x 2.121 x 1.193 x 0.7113 x 0.4692 x 1.539 x
Free Cash Flow 1 -170 -313 -42.6 -301 -597 -2,142
ROE (net income / shareholders' equity) 16.6% 20.2% 32.2% 48.9% 53.6% 40.8%
ROA (Net income/ Total Assets) 7.59% 10.7% 13.2% 15.2% 12.9% 11.5%
Assets 1 1,219 1,271 2,167 4,285 9,090 11,872
Book Value Per Share 2 3.030 3.730 5.150 8.170 13.60 19.70
Cash Flow per Share 2 0.3900 0.6100 1.390 3.050 6.550 3.010
Capex 1 77.7 69.8 147 268 337 755
Capex / Sales 9.71% 6.7% 10.72% 14.38% 14.46% 16.87%
Announcement Date 10/03/18 08/03/19 06/03/20 05/03/21 04/03/22 10/03/23
1TRY in Million2TRY
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Sector Other Pharmaceuticals

1st Jan change Capi.
DEVA HOLDING Stock Deva Holding
+5.16% 485M
NOVO NORDISK A/S Stock Novo Nordisk A/S
+31.40% 588B
JOHNSON & JOHNSON Stock Johnson & Johnson
-3.32% 364B
MERCK & CO., INC. Stock Merck & Co., Inc.
+19.52% 326B
ABBVIE INC. Stock AbbVie Inc.
+5.27% 285B
ASTRAZENECA PLC Stock AstraZeneca PLC
+15.34% 239B
NOVARTIS AG Stock Novartis AG
+9.99% 210B
ROCHE HOLDING AG Stock Roche Holding AG
-6.99% 200B
AMGEN INC. Stock Amgen Inc.
+9.52% 167B
PFIZER, INC. Stock Pfizer, Inc.
-0.47% 161B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. DEVA Stock
  4. Financials Deva Holding